# Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

> **NCT00823524** · PHASE1,PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 47 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Lymphoproliferative Disorder
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** donor natural killer cell infusion

## Key facts

- **NCT ID:** NCT00823524
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2013-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00823524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00823524, "Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00823524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*